Following its $20 billion asset swap with GlaxoSmithKline last year, Novartis is to split its pharmaceutical division in two, creating two business units, with the former single business un
As the US FDA moves towards issuing final guidelines on biosimilars, recent research with specialists in five main therapy areas suggests they are willing to embrace them if efficacy and safety
Novartis says its chimeric antigen receptors (CAR-T) candidate is on track for filing in 2017, which could make it the first of the novel drugs to hit the market.
Xolair has gained EU approval as the first ever add-on therapy to treat chronic spontaneous urticaria (CSU) in adult and adolescent patients with inadequate response to H1-antihistamine tre